Karine Peignaux

Learn More
PURPOSE EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis. EXPERIMENTAL DESIGN This randomized phase II trial enrolled 78 FIGO stage IB2-IIIB(More)
BACKGROUND Chemoradiation is the standard treatment for anal cancer. 3D conformal radiotherapy (3D-CRT) is usually split in 2 sequences with a therapeutic break (gap) in between. Intensity-modulated radiation therapy (IMRT) makes it possible to reduce treatment time by abandoning this gap. The purpose of this study was to compare outcomes and toxicities in(More)
BACKGROUND Monocentric cohorts suggested that radiation-induced CD8 T-lymphocyte apoptosis (RILA) can predict late toxicity after curative intent radiotherapy (RT). We assessed the role of RILA as a predictor of breast fibrosis (bf +) after adjuvant breast RT in a prospective multicenter trial. METHODS A total of 502 breast-cancer patients (pts) treated(More)
Data from a randomized phase II trial of radio-chemotherapy +/-Cetuximab for locally advanced cervix carcinoma Disclosure: All the authors declared no conflict of interest Running Title: PIK3CA-mutations predictive of bad response in cervix cancer Abstract 258 words Text 3165 words Author manuscripts have been peer reviewed and accepted for publication but(More)
  • 1